Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Candesartan cilexetil (Atacand), 16 mg Clear all
Enrolling by invitation Phase 2 Interventional

Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury

NCT05826912
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Atorvastatin Calcium, Minocycline Hydrochloride, Candesartan Cilexetil, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
18
States / cities
San Francisco, California • Indianapolis, Indiana • Lexington, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 8, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial

NCT00605072
View directory record Official record
Conditions
Cognitive Impairment, Hypertension, Aging
Interventions
candesartan, lisinopril, hydrochlorothiazide, nifedipine, long acting, metoprolol, long-acting
Drug
Lead sponsor
University of Southern California
Other
Eligibility
60 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 8, 2026, 10:15 AM EDT
Completed Phase 1 Interventional

An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence

NCT01062451
View directory record Official record
Conditions
Methamphetamine Dependence, Methamphetamine Abuse, Substance Abuse
Interventions
Perindopril, Placebo, Candesartan
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 8, 2026, 10:15 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Adiposity and Endothelin Receptor Function

NCT03583866
View directory record Official record
Conditions
Hypertension
Interventions
Candesartan, Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 8, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Candesartan's Effects on Alzheimer's Disease And Related Biomarkers

NCT02646982
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Placebo, Candesartan
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 8, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

NCT01788358
View directory record Official record
Conditions
Hypertension
Interventions
Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
39
States / cities
Foley, Alabama • Carmichael, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 8, 2026, 10:15 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 8, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial

NCT00227318
View directory record Official record
Conditions
Hypertension
Interventions
ATACAND
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
42
States / cities
Mobile, Alabama • Long Beach, California • Redondo Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2011 · Synced Oct 8, 2026, 10:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function

NCT01678794
View directory record Official record
Conditions
Cardiorenal Syndrome (CRS)
Interventions
Candesartan, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 8, 2026, 10:15 AM EDT
Completed Phase 2 Interventional

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension

NCT01303783
View directory record Official record
Conditions
Hypertension, Essential
Interventions
Candesartan cilexetil (Atacand), 4 mg, Candesartan cilexetil (Atacand), 8 mg, Nifedipine GITS (Adalat, BAYA1040), 20 mg, Nifedipine GITS (Adalat, BAYA1040), 30 mg, Nifedipine GITS (Adalat, BAYA1040), 60 mg, Placebo, Candesartan cilexetil (Atacand), 16 mg, Candesartan cilexetil (Atacand), 32 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Coral Gables, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 8, 2026, 10:15 AM EDT
Completed No phase listed Observational

Genetic Epidemiology of Responses to Antihypertensives

NCT00005520
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Hypertension
Interventions
Hydrochlorothiazide, Candesartan
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 8, 2026, 10:15 AM EDT